GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ABL Bio Inc (XKRX:298380) » Definitions » Inventories, Finished Goods

ABL Bio (XKRX:298380) Inventories, Finished Goods : ₩0 Mil (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is ABL Bio Inventories, Finished Goods?


ABL Bio Inventories, Finished Goods Historical Data

The historical data trend for ABL Bio's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ABL Bio Inventories, Finished Goods Chart

ABL Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only - - - - -

ABL Bio Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

ABL Bio Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.


ABL Bio Business Description

Industry
Traded in Other Exchanges
N/A
Address
2nd Floor, 16 Daewangpangyo-Ro 712, Beon-Gil, Bundang-Gu, Gyeonggi-do, Seongnam-si, KOR, 13488
ABL Bio Inc is a Korean biotech research company. The company is engaged in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline products include ABL001 an Bispecific Antibody, ABL201-205 an Antibody Drug Conjugate, T cell engager, Dual Immune Cell Targeting BsAb an Immuno-Oncology, ABL301 an BBB-Penetrating Bispecific Antibody.

ABL Bio Headlines

No Headlines